Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
AlloLife is a South Korean biotechnology company dedicated to the development of allogeneic cell therapies and regenerative medicine solutions. The company leverages its expertise in mesenchymal stem cells (MSCs) and natural killer (NK) cells to create "off-the-shelf" treatments for various immune-related and degenerative conditions. In addition to its therapeutic pipeline, AlloLife provides premium cell banking services and develops exosome-based products for the aesthetics and wellness markets. By standardizing cell manufacturing and storage, the company aims to make advanced regenerative therapies more accessible to a global patient base. Their research also extends to the development of specialized culture media and optimized cell expansion technologies to ensure high-quality therapeutic outputs.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on 알로라이프.